Evidence map›Paper›PMID 37023130›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

STING-dependent interferon signatures restrict osteoclast differentiation and bone loss in mice.

Susan MacLauchlan, Priyanka Kushwaha, Albert Tai, Sijia Chen, Catherine Manning, Gaurav Swarnkar, Yousef Abu-Amer, Katherine A Fitzgerald, Shruti Sharma, Ellen M Gravallese

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Therapeutic targeting of the cGAS-STING pathway in human disease.The Journal of clinical investigation · 2026
    Review
  7. Interferon-JAK-STAT Axis in Bone Metabolism.Current osteoporosis reports · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. OptimizingPeerJ · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Susan MacLauchlanDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.ORCID 0000-0001-9689-0826
Priyanka KushwahaDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
Albert TaiDepartment of Immunology, Tufts University School of Medicine, Boston, MA 02111.ORCID 0000-0001-7771-0850
Sijia ChenDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
Catherine ManningDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.ORCID 0000-0002-7654-2848
Gaurav SwarnkarDepartment of Orthopedics and Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, MO 63110.ORCID 0000-0001-6052-4971
Yousef Abu-AmerDepartment of Orthopedics and Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, MO 63110.ORCID 0000-0002-5890-5086
Katherine A FitzgeraldDepartment of Medicine, Program in Innate Immunity, University of Massachusetts Chan Medical School, Worcester, MA 01655.
Shruti SharmaDepartment of Immunology, Tufts University School of Medicine, Boston, MA 02111.ORCID 0000-0001-5423-1072
Ellen M GravalleseDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.ORCID 0000-0002-0981-0996
Brigham and Women's Hospital · USTufts University · USWashington University in St. Louis · USUniversity of Massachusetts Chan Medical School · US

Funding

Translational Imaging and Phenotyping CoreP30AR075042 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Marie Demay · 2019 to 2026
$7.4M
Regulation of Lupus by Cytosolic DNA SensorsR01AI128358 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, KATHERINE A., MARSHAK-ROTHSTEIN, ANN · 2017 to 2021
$2.7M
Intracellular nucleic acid sensing and age-related chronic inflammationR01AI142005 · NIAID · TUFTS UNIVERSITY BOSTON · PI SHARMA, SHRUTI · 2019 to 2023
$2.3M
The STING pathway and cytosolic nucleic acid sensors in bone homeostasisR01AR071037 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GRAVALLESE, ELLEN M · 2017 to 2021
$1.9M
Mechanisms of Physiologic and Pathologic OsteoclastogenesisR01AR072623 · NIAMS · WASHINGTON UNIVERSITY · PI ABU-AMER, YOUSEF · 2018 to 2022
$1.7M
TET2-driven Clonal Hematopoiesis Promotes Disease Progression in Rheumatoid ArthritisK01AR075896 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MACLAUCHLAN, SUSAN C. · 2019 to 2023
$545k
NIAID NIH HHS R01 AI128358NIAID NIH HHS R01 AI142005NIAMS NIH HHS K01 AR075896NIAMS NIH HHS P30 AR075042NIAMS NIH HHS R01 AR071037NIAMS NIH HHS R01 AR072623
6 · The paper itself

Abstract

Stimulator of interferon genes (STING) is a key mediator of type-I interferon (IFN-I) signaling in response to a variety of stimuli, but the contribution of STING to homeostatic processes is not fully characterized. Previous studies showed that ligand activation of STING limits osteoclast differentiation in vitro through the induction of IFNβ and IFN-I interferon-stimulated genes (ISGs). In a disease model (SAVI) driven by the V154M gain-of-function mutation in STING, fewer osteoclasts form from SAVI precursors in response to receptor activator of NF-kappaB ligand (RANKL) in an IFN-I-dependent manner. Due to the described role of STING-mediated regulation of osteoclastogenesis in activation settings, we sought to determine whether basal STING signaling contributes to bone homeostasis, an unexplored area. Using whole-body and myeloid-specific deficiency, we show that STING signaling prevents trabecular bone loss in mice over time and that myeloid-restricted STING activity is sufficient for this effect. STING-deficient osteoclast precursors differentiate with greater efficiency than wild types. RNA sequencing of wild-type and STING-deficient osteoclast precursor cells and differentiating osteoclasts reveals unique clusters of ISGs including a previously undescribed ISG set expressed in RANKL naïve precursors (tonic expression) and down-regulated during differentiation. We identify a 50 gene tonic ISG signature that is STING dependent and shapes osteoclast differentiation. From this list, we identify interferon-stimulated gene 15 (ISG15) as a tonic STING-regulated ISG that limits osteoclast formation. Thus, STING is an important upstream regulator of tonic IFN-I signatures shaping the commitment to osteoclast fates, providing evidence for a nuanced and unique role for this pathway in bone homeostasis.

Indexed as

OsteoclastsSignal TransductionAnimalsCell DifferentiationInterferonsLigandsMiceMice, Inbred C57BLRANK LigandSTING ProteinInterferonsLigandsRANK LigandSting1 protein, mouseSTING Proteinbone homeostasisinterferonosteoimmunologySTING

Identifiers

PMID37023130
PMCPMC10104545
OpenAlexW4362657175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.